Jindike's trivalent flu vaccine wins approval but has no product to sell, may trigger delisting risk warning

Becton Dickinson agreed to invest $3 billion to bring manufacturing of essential medical products to the United States, part of a broader plan to invest $19 billion in the country over several years across capital, operations and supply-chain initiatives, President Donald Trump said Monday in a post on Truth Social. More than $1 billion of that $3 billion will go to Nebraska to ramp up production of numerous products, including needles made with American steel, and BD expects to increase domestic production of essential medical consumables by about 5 billion units annually, raising the share of such products supplied from within the U.S. to roughly 80%. Separately, Viatris entered a definitive agreement to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, in a deal expected to close by the end of 2026 that adds the patent-protected pain therapies EXPAREL and ZILRETTA; Pacira generated approximately $746 million in total revenue and about $177 million in adjusted EBITDA in the twelve months ended June 30, 2026. CSL and Alentis Therapeutics entered an exclusive global partnership to co-develop and co-promote lixudebart for rare kidney, liver and other diseases, with CSL making an initial payment of $355 million and Alentis eligible for up to $1.2 billion in commercial milestone payments, and the companies sharing global profits 55% to CSL and 45% to Alentis once the drug is commercialized. Novavax and Moderna traded flat in the premarket on Tuesday after the WHO said Russian officials had traced all contacts of a plague research lab employee who died of pneumonia of an unknown cause, though Novavax closed 20% higher and Moderna added 7% on Monday after Russia's Rospotrebnadzor reported the death of the 28-year-old worker at the Irkutsk Research Anti-Plague Institute of Siberia.

GSK will expand its Pennsylvania operations with a more than $800M investment in Montgomery County, a move expected to add roughly 300 jobs over the next five years. The pharma company already employs about 4,500 full-time workers in the state. The expansion, set to begin next year in Upper Merion Township, will involve demolishing current buildings and constructing new ones, including a commercial-scale biologics manufacturing facility, an R&D pilot plant, a centralized quality control lab, and a manufacturing science and technology hub. The new investment follows an October 2024 announcement of an up to $800M commitment to boost R&D and manufacturing at a facility in Lancaster County.

Olymvax Biopharmaceuticals disclosed a litigation progress announcement on the evening of October 9. The first-instance judgment in a technology transfer contract dispute has been served. The court found the plaintiff to be in breach of contract, and the listed company's core claim to terminate the contract was upheld. The case stems from a Technology Transfer Contract signed on June 22, 2011. Plaintiff Wang Jianhua filed suit in December 2025, claiming product royalties and liquidated damages totaling 19.2 million yuan, which was amended to 20.88 million yuan in January 2026. The company subsequently filed a counterclaim, seeking confirmation of contract termination and demanding a refund of the price plus liquidated damages totaling 9.7 million yuan. The court found that the plaintiff failed to fully perform contractual obligations and constituted a breach, and that the contract was terminated on January 27, 2026. It ordered the company to pay the plaintiff 2 million yuan and the plaintiff to pay the company 1 million yuan in liquidated damages. After offsetting the two amounts, the company's actual net burden is 1 million yuan. Of the plaintiff's 20.88 million yuan claim, the 2 million yuan awarded is less than one-tenth of the amount sought. The company's full-year 2025 revenue was 704 million yuan and net profit attributable to the parent was 22.2601 million yuan. The 1 million yuan net expense has limited impact on current-period profit and loss, but the case is still within the appeal period and the first-instance judgment has not yet taken effect. On the operational side, the company achieved revenue of 361 million yuan in the first half of 2026, up 18.14 percent year on year. Affected by factors including back taxes, net profit attributable to the parent was negative 32.8726 million yuan, swinging from profit to loss year on year. Its recombinant Staphylococcus aureus vaccine completed unblinding of the Phase III clinical trial in July 2026, with protective efficacy reaching 73.25 percent, exceeding the pre-specified 60 percent target, making it the world's first Staphylococcus aureus vaccine to complete Phase III clinical trials. The company aims to formally file for production approval before the end of 2026.

MicuRx Pharmaceuticals has signed an exclusive license agreement and a platform technology collaboration agreement with Switzerland's ClearideBio for the MRX-23 project. The nominal cap on milestone payments for the development, registration, and sales of MRX-23 totals 223 million US dollars, while the cap for all platform collaboration projects, if all options are exercised and all milestones are achieved, totals 750 million US dollars. Under the agreement, an upfront payment of 1 million US dollars is payable as agreed after the agreement takes effect and is non-refundable, and near-term development milestone payments are triggered by the first approval of a clinical trial application for the licensed product. Biwin Storage Technology announced that as of September 30, 2026, it had cumulatively repurchased 1,044,700 shares, accounting for 0.22 percent of total share capital, with a total payment of 222 million yuan. The repurchase plan is expected to involve a total amount of 200 million to 250 million yuan. Sino Medical Sciences Technology's coronary balloon dilatation catheter has received approval from Colombia's INVIMA and obtained a medical device registration certificate. Jiangsu Jindike Biotechnology's trivalent influenza vaccine has obtained a drug registration certificate, but the company expects full-year revenue may fall below 100 million yuan and it will not be able to turn a profit. If it triggers the financial delisting risk warning conditions, the Shanghai Stock Exchange will impose a delisting risk warning on the company's shares.